Alexion Pharmaceuticals, Inc.’s Post

As we delve deeper into the possibilities of generative AI, it is inspiring to witness how its application in whole genome sequencing could revolutionize the identification of patients with rare diseases. This innovation holds immense promise for delivering transformative therapies to those who need them most.

Shortening the time to diagnosis is life changing and life saving for patients.

DID YOU KNOW❓ Every person's body responds to treatment differently. Disease can leave unique signatures within tissues, affecting how therapies work. Targeted Bioscience helps researchers visualize these hidden differences, opening the door to more personalized and effective treatments. Precision medicine starts here. Find out how: 👉 https://lnkd.in/dZfxKFnE

The mood-music emanating from the TBI and from central government is, for me, heartening. I have witnessed first-hand for 30 years the counterproductive friction, resistance and the costs - in terms of both population health outcomes and the UK economy - to research and development from using resources such as anonymous, NHS routine data (real world data [RWD]). Hopefully, we are at an inflection point and things will now change; and quickly. However, it is essential that people in the public sector and the university sector recognise that this should be driven by the private sector, at least in a public-private partnership. The public sector, the university sector, and wider society in turn then benefit from innovation, and wealth & job creation. Fingers crossed!

#Genomics has established itself as essential to healthcare delivery, promising more accurate disease diagnosis 🧪 personalised medicine approaches 💊 faster drug development 🔬 and preventative approaches 🏃♀️ But how is it really being used today, what challenges can the HealthTech sector help overcome if it is to have a daily impact on everyone's health, and what - if any - role does #artificialintelligence have to play in it? Don't know your WGS from your PGx? Read this 5 Minute HealthTech Jargon Buster from Romilly Life Sciences' Saoirse Wilson and all will become clear!

🌍 Advancing Research for #RareDiseases: Nano4Rare and Fabry Disease Rare diseases affect millions globally, yet treatments remain scarce. At #Nano4Rare, we are developing an innovative therapy called #nanoGLA to combat #FabryDisease, the second most prevalent Lysosomal Storage Disorder. This groundbreaking approach uses nanotechnology to enhance enzyme replacement therapies, offering new hope to patients. 🤝 Organizations such as the Federación Española de Enfermedades Raras in Spain and EURORDIS-Rare Diseases Europe have been vital in advocating for patients, while fostering research and collaboration across Europe. 🔬 The future of rare disease treatment relies on continued innovation, collaboration, and awareness. Let’s keep driving this mission forward!

🌍 Rare Diseases: A New Frontier in Innovation 🌐 Global Impact: 350-400 million people worldwide are affected by rare diseases, yet many still lack effective treatments. 🧬 Genetic Roots: 80% of rare diseases are genetic, highlighting the urgent need for advanced therapies. 🚀 ⚠️ Challenges in Development: Small populations and complex trial designs make developing treatments for rare diseases challenging. 🤝 Global Collaboration: Working together across borders is essential for unlocking life-saving treatments for these conditions. At Credevo, we support every step of the journey—from clinical trial design to regulatory approvals. Let’s speed up drug development together! 🌱💡 🔍 Want to learn more? https://lnkd.in/gsTqYtKV #RareDisease #OrphanDrugs #ClinicalTrials #DrugDevelopment #PharmaInnovation #Healthcare

Today, on February 29th, we join the global #community in commemorating World #Rare Disease Day, a vital initiative to amplify #awareness around the harsh realities of these often-overlooked #pathologies. At NANOMOL TECHNOLOGIES, we are resolute in our dedication to creating awareness and addressing the significant challenges posed by rare #diseases. 🌐 Global #Health Implications: Rare diseases pose a profound #challenge to global public health. With limited understanding, resources, and #treatment options, individuals with rare diseases face substantial hurdles in obtaining timely and effective #care. The struggle is not only a personal one but also extends to the broader #healthcare ecosystem:   ➡Over 300 million people #worldwide suffer from a rare disease.  ➡72% of rare diseases are #genetic in origin, affecting individuals from birth.  ➡The lack of scientific #knowledge often delays #diagnosis and treatment, exacerbating the impact on #patients. 🔬 Innovating in Real-Time: We reaffirm our ongoing commitment to nanomedicine #research, #development, and GMP #manufacturing. In the present moment, we actively immerse ourselves in the #development of nanomedicine, adhering to #GMP standards. Our mission is to pioneer advanced and effective treatments for #Fabry disease, contributing to a substantial improvement in the lives of individuals grappling with the #challenges of rare diseases. Together, we are shaping a present filled with hope and enhancing the #quality of life for individuals affected by rare diseases.    #WorldRareDiseaseDay #GlobalHealthChallenge #Innovation #Nanomedicine #FabryDisease 

🔬 𝐄𝐦𝐛𝐫𝐚𝐜𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 🚀 Dr. Parit Plainkum, Asst. Hospital Director, emphasises the power of collaboration between technology and healthcare. Predictive algorithms for cardiovascular events and genetic testing empower individuals to take proactive measures.🤖 For more information: https://buff.ly/3xtA8pv #NorwayAsiaBusinessSummitMagazine #SamitivejHospital #InnovationInHealthcare #TNCCMembers #NorwayAsiaBusinessReview

Transforming Healthcare with the 𝐏𝐫𝐞𝐜𝐢𝐬𝐞-𝐒𝐆100𝐊 𝐆𝐞𝐧𝐨𝐦𝐞 𝐏𝐫𝐨𝐣𝐞𝐜𝐭! The quest to map the DNA of 100,000 people has reached the halfway mark! 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬: 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐧𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: Tailored treatments and optimized drug dosages based on individual genetic profiles. Early detection of cancer and chronic disease risks. How might early detection of cancer and chronic disease risks revolutionise preventive care? 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐚𝐭𝐢𝐧𝐠 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: How will this advance our understanding of genetic contributions to diseases and treatments? 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐩𝐚𝐜𝐭: Fills the gap of under-represented Asian genomes in global studies. How will such data influence decision making regarding global healthcare policies? A huge shoutout to Illumina and NovogeneAIT for their remarkable contributions. Explore my other posts on LinkedIn to find out more about 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧. Taken from: https://lnkd.in/dtFe5vgD #HealthcareInnovation #DrivePatientCare